Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Advanced or Recurrent Solid Tumors|Breast Neoplasm
Interventions: BIOLOGICAL: Injections Subcutaneously Talazoparib|DRUG: Oral capsules Talazoparib
Sponsor: Center Trials & Treatment
Collaborators: BioGene Pharmaceutical